色偷偷wwww88888,少妇熟女高潮流白浆,极品人妻VIDEOSSS人妻,九九热在线视频观看这里只有精品

中裕新藥,TaiMed Biologics,  
中裕新藥股份有限公司(原宇昌生技)成立于2007年9月。本公司以成為世界創(chuàng)新技術(shù)為基礎(chǔ)的生物科技新藥開發(fā)公司為目標(biāo)，從事治療及預(yù)防感染性疾病的新藥研發(fā)。現(xiàn)有主要股東包括潤泰集團(tuán)、國發(fā)基金、合一創(chuàng)投及上智創(chuàng)投。
2007年中裕從美國Gennentech公司取得全球市場獨(dú)家授權(quán)，技術(shù)移轉(zhuǎn)一個治療愛滋病的單株抗體生物制劑TMB-355(lbalizumab)，并持續(xù)在美國進(jìn)行第二個臨床二期的試驗(yàn)，預(yù)計(jì)2010年底完成所有病人的療程及數(shù)據(jù)分析。另外，中裕于2008年正式進(jìn)駐于位于南港的中央研究院育成中心，設(shè)立實(shí)驗(yàn)室。并于年底與中央研究院簽「獨(dú)家授權(quán)協(xié)議」，技術(shù)移轉(zhuǎn)治療流行性感冒藥物零流感，并繼續(xù)其制程 ??及臨床試驗(yàn)的開發(fā)。
中裕新藥初期的研究發(fā)展將著重于TMB-355及后續(xù)藥物的臨床試驗(yàn)開發(fā)及技術(shù)移轉(zhuǎn)，藥物標(biāo)的物的搜尋、驗(yàn)證，生物功能的探討，以及新產(chǎn)品開發(fā)的可行性評估。由于愛滋病新藥TMB-355即將完成臨床二期試驗(yàn)，且初期的數(shù)據(jù)證明療效，中裕在公司短期及中期的經(jīng)營策略上，保有相當(dāng)?shù)膹椥浴?br/>
創(chuàng)辦人
TMB創(chuàng)辦于2007年9月4日，其目的是為在臺灣創(chuàng)造一家世界級的、以創(chuàng)新為基礎(chǔ)的生物技術(shù)公司。

創(chuàng)辦人如下：
何大一博士
中研院院士，中裕新藥最高技術(shù)咨詢顧問及前任董事。何博士是25年來世界AIDS研究的主要權(quán)威人士，發(fā)表論文超過350篇?，F(xiàn)為美國Aaron Diamond AIDS研究中心主任及CEO，洛克菲勒大學(xué)Irene Diamond執(zhí)行長。他捍衛(wèi)的高效抗逆轉(zhuǎn)錄病毒療法能前所未有地控制病患的HIV病毒。何博士的諸多榮譽(yù)中，包括入選美國藝術(shù)與科學(xué)院、美國國家科學(xué)院醫(yī)學(xué)研究所、臺灣中央研究院、中國科學(xué)院。
陳良博博士
中研院院士，哈佛大學(xué)榮譽(yù)教授，現(xiàn)為中裕新藥美國子公司(TMB USA Inc)董事長。
蔡英文博士
臺灣行政院前副院長，前陸委會主委，為本公司第一任董事長

TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world. The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. A phase-2b clinical trial is currently underway and we expect the trial to be completed in Q1 2011.
TaiMed Biologics has made much progress in its short existence. An outstanding management team with industry experience has been assembled in both Taiwan and the US. TMB is committed to evaluating new business development opportunities. In Q4 of 2008, TMB in-licensed Tamiphosphor, a neuraminidase inhibitor for the treatment of influenza, from Academia Sinica in Taiwan and has taken that program forward. In early 2009, drug synthesis work has been conducted as well as a collaboration with NIH has been established for cross resistance testing. In addition, in collaboration with the Aaron Diamond AIDS Research Center, the development of Ibalizumab for prevention of HIV infection will be explored in a phase 1 trial in 2H 2010. This project has received grant funding from the Bill and Melinda Gates Foundation.
TaiMed Biologics is committed to conducting business with integrity and passion. We remain to be forward-thinking and utilize our resources wisely and efficiently in order to meet our long-term objectives.